NO20043549L - Anvendelse av benzotiazepiner som har aktivitet som inhibitorer av tynntarm-gallesyretransport for a redusere kolesterolemi - Google Patents
Anvendelse av benzotiazepiner som har aktivitet som inhibitorer av tynntarm-gallesyretransport for a redusere kolesterolemiInfo
- Publication number
- NO20043549L NO20043549L NO20043549A NO20043549A NO20043549L NO 20043549 L NO20043549 L NO 20043549L NO 20043549 A NO20043549 A NO 20043549A NO 20043549 A NO20043549 A NO 20043549A NO 20043549 L NO20043549 L NO 20043549L
- Authority
- NO
- Norway
- Prior art keywords
- benzothiazepines
- inhibitors
- activity
- bile acid
- small intestinal
- Prior art date
Links
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
- 150000007657 benzothiazepines Chemical class 0.000 title 1
- 239000003613 bile acid Substances 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0201850.5A GB0201850D0 (en) | 2002-01-26 | 2002-01-26 | Therapeutic treatment |
| PCT/GB2003/000350 WO2003061663A1 (en) | 2002-01-26 | 2003-01-23 | Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043549L true NO20043549L (no) | 2004-08-25 |
Family
ID=9929835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043549A NO20043549L (no) | 2002-01-26 | 2004-08-25 | Anvendelse av benzotiazepiner som har aktivitet som inhibitorer av tynntarm-gallesyretransport for a redusere kolesterolemi |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050124557A1 (pl) |
| EP (1) | EP1478368A1 (pl) |
| JP (1) | JP2005523255A (pl) |
| KR (1) | KR20040079949A (pl) |
| CN (1) | CN1617729A (pl) |
| BR (1) | BR0307093A (pl) |
| CA (1) | CA2473721A1 (pl) |
| GB (1) | GB0201850D0 (pl) |
| HU (1) | HUP0500009A3 (pl) |
| IS (1) | IS7357A (pl) |
| MX (1) | MXPA04007201A (pl) |
| NO (1) | NO20043549L (pl) |
| PL (1) | PL371521A1 (pl) |
| RU (1) | RU2004126148A (pl) |
| TW (1) | TW200302089A (pl) |
| WO (1) | WO2003061663A1 (pl) |
| ZA (1) | ZA200405866B (pl) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| MY131995A (en) | 2001-09-08 | 2007-09-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| CA2512899A1 (en) | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) * | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| EP2287166A3 (en) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| EP2367554A4 (en) * | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid reflux inhibitor for the treatment of obesity and diabetes |
| EP3593802A3 (en) | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| CN103539791B (zh) | 2010-09-22 | 2017-01-11 | 艾尼纳制药公司 | Gpr119 受体调节剂和对与其相关的障碍的治疗 |
| EP3777864A1 (en) | 2010-11-04 | 2021-02-17 | Albireo AB | Ibat inhibitors for the treatment of liver diseases |
| KR101890960B1 (ko) * | 2010-11-08 | 2018-09-28 | 알비레오 에이비 | Ⅰｂａｔ 억제제 및 담즙산 바인더를 포함하는 약학적 조합물 |
| US20120114588A1 (en) * | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
| JP2013542953A (ja) * | 2010-11-08 | 2013-11-28 | アルビレオ アクチエボラグ | 代謝障害および関連状態の処置用のｉｂａｔ阻害剤 |
| US20130109671A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases |
| SG10201903512SA (en) | 2011-10-28 | 2019-05-30 | Lumena Pharmaceuticals Inc | Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| WO2016209809A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| CN108601744B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| WO2017138878A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
| WO2019032027A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| IL279464B2 (en) | 2018-06-20 | 2025-12-01 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN118834175A (zh) | 2019-02-06 | 2024-10-25 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| SMT202300020T1 (it) | 2019-02-06 | 2023-03-17 | Albireo Ab | Composti di benzotiadiazepine e loro uso come modulatori degli acidi biliari |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4069247B1 (en) | 2019-12-04 | 2025-03-26 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
| BR112022010505A2 (pt) | 2019-12-04 | 2022-09-06 | Albireo Ab | Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar |
| CN114761080B (zh) | 2019-12-04 | 2024-07-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| WO2021110883A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AR120682A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar |
| TWI867107B (zh) | 2019-12-04 | 2024-12-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES3002777T3 (en) | 2020-08-03 | 2025-03-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
| CN116583504A (zh) | 2020-12-04 | 2023-08-11 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| WO2023203248A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
| WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| AU2023304672A1 (en) | 2022-07-05 | 2025-01-02 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| KR20250110930A (ko) | 2022-12-09 | 2025-07-21 | 알비레오 에이비 | 신장 질병 치료용 asbt 억제제 |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900757A (en) * | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
| ATE242258T1 (de) * | 1997-03-14 | 2003-06-15 | Aventis Pharma Gmbh | Hypolipidemische 1,4-benzothiazepin-1,1-dioxide |
| SE0000772D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| EG26979A (en) * | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
-
2002
- 2002-01-26 GB GBGB0201850.5A patent/GB0201850D0/en not_active Ceased
-
2003
- 2003-01-23 RU RU2004126148/14A patent/RU2004126148A/ru not_active Application Discontinuation
- 2003-01-23 EP EP03731763A patent/EP1478368A1/en not_active Withdrawn
- 2003-01-23 CA CA002473721A patent/CA2473721A1/en not_active Abandoned
- 2003-01-23 MX MXPA04007201A patent/MXPA04007201A/es not_active Application Discontinuation
- 2003-01-23 BR BR0307093-0A patent/BR0307093A/pt not_active Application Discontinuation
- 2003-01-23 PL PL03371521A patent/PL371521A1/pl not_active Application Discontinuation
- 2003-01-23 HU HU0500009A patent/HUP0500009A3/hu unknown
- 2003-01-23 JP JP2003561607A patent/JP2005523255A/ja active Pending
- 2003-01-23 KR KR10-2004-7011445A patent/KR20040079949A/ko not_active Withdrawn
- 2003-01-23 CN CNA038023547A patent/CN1617729A/zh active Pending
- 2003-01-23 WO PCT/GB2003/000350 patent/WO2003061663A1/en not_active Ceased
- 2003-01-23 US US10/502,355 patent/US20050124557A1/en not_active Abandoned
- 2003-01-24 TW TW092101585A patent/TW200302089A/zh unknown
-
2004
- 2004-07-21 IS IS7357A patent/IS7357A/is unknown
- 2004-07-22 ZA ZA200405866A patent/ZA200405866B/en unknown
- 2004-08-25 NO NO20043549A patent/NO20043549L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0500009A2 (hu) | 2005-04-28 |
| HUP0500009A3 (en) | 2006-05-29 |
| IS7357A (is) | 2004-07-21 |
| MXPA04007201A (es) | 2004-11-26 |
| RU2004126148A (ru) | 2005-05-27 |
| JP2005523255A (ja) | 2005-08-04 |
| US20050124557A1 (en) | 2005-06-09 |
| CN1617729A (zh) | 2005-05-18 |
| WO2003061663A1 (en) | 2003-07-31 |
| ZA200405866B (en) | 2006-07-26 |
| BR0307093A (pt) | 2004-12-28 |
| PL371521A1 (pl) | 2005-06-27 |
| EP1478368A1 (en) | 2004-11-24 |
| TW200302089A (en) | 2003-08-01 |
| CA2473721A1 (en) | 2003-07-31 |
| GB0201850D0 (en) | 2002-03-13 |
| KR20040079949A (ko) | 2004-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20043549L (no) | Anvendelse av benzotiazepiner som har aktivitet som inhibitorer av tynntarm-gallesyretransport for a redusere kolesterolemi | |
| IL166523A0 (en) | Generalized metronome for modification of biorhythmic activity | |
| IL214281A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| CY2016042I2 (el) | Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων | |
| DK1660431T3 (da) | Phenoxyeddikesyrederivater | |
| NO20054880D0 (no) | Azaspiroalkanderivater som inhibitorer av metallproeaser | |
| DK2178840T3 (da) | Azabiphenylaminobenzoesyre-derivater som dhodh-hæmmere | |
| DK1633748T3 (da) | Quinolinfrtibsyrt dom phosphodiesteraseinhibitorer | |
| DK2121614T3 (da) | Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer | |
| DK1789041T3 (da) | Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer | |
| DK1797042T3 (da) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| IL183599A0 (en) | Novel hydantoin derivatives as metalloproteinase inhibitors | |
| WO2006099468A3 (en) | Process for the purification of duloxetine hydrochloride | |
| ZA200705076B (en) | Novel hydantoin derivatives as metalloproteinase inhibitors | |
| DE602004011548D1 (de) | 4-aminochinolin-3-carbonsäureamid-derivate als pde4-hemmer | |
| IL164645A0 (en) | Polymorph of 4-Ä2-Ä1-(2-ethoxyethyl)-1H-benzidimazole-2-YLÜ-1-piperidinylÜethylÜ-??-dimethyl-benzenoacetic acid | |
| EP1765761A4 (en) | NOVEL ANALOGUES OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID | |
| IS2136B (is) | Aðferð til nýmyndunar í iðnaði á metýldíester 5-amínó-3-karboxýmetýl-4-sýanó-2-þíófenkarboxýlsýru | |
| DK1856063T3 (da) | 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme | |
| SI1513806T1 (sl) | Sulfonske kislinske soli derivatov mandljeve kisline | |
| IL164267A0 (en) | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | |
| DK1644350T3 (da) | Sullfamatbenzothiophenderivater som steroidsulfataseinhibitorer | |
| DK1224164T3 (da) | Hydroxaminsyrederivat som inhibitor for produktion af oplöselig human CD23 | |
| AU2003208926A1 (en) | Integration of at least two processes to re-use acid | |
| AU2003247209A1 (en) | Organic acid salt of amlodipine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |